10-Q Filing

GUARDANT HEALTH, INC. CIK: 1576280 Q1 2021

Filing Information

Form Type	10-Q
Accession Number	`0001576280-21-000062`
Period End Date	20210331
Filing Date	20210506
Fiscal Year	2021
Fiscal Period	Q1
XBRL Instance	gh-20210331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 73 Income Statement 40 Cash Flow Statement 80 Stockholders Equity 22 Comprehensive Income 14

Balance Sheet 73 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$832.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$152.24M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$869.37M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$961.90M	USD	Point-in-time
Short-term marketable securities	`MarketableSecuritiesCurrent`	$1.07B	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$53.30M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$48.04M	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common stock, par value (in usd per share)	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Inventory	`InventoryNet`	$22.72M	USD	Point-in-time
Inventory	`InventoryNet`	$28.88M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$17.47M	USD	Point-in-time
Prepaid expenses and other current assets, net	`PrepaidExpenseAndOtherAssetsCurrent`	$15.68M	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.03B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.89B	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	100.21M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	101.09M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	101.09M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	$246.60M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	100.21M	shares	Point-in-time
Long-term marketable securities	`MarketableSecuritiesNoncurrent`	-	USD	Point-in-time
Assets	`Assets`	$2.35B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$71.77M	USD	Point-in-time
Assets	`Assets`	$2.27B	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$62.78M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$205.67M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$37.34M	USD	Point-in-time
Liabilities	`Liabilities`	$1.44B	USD	Point-in-time
Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.67M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$16.16M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Goodwill	`Goodwill`	$3.29M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$17.30M	USD	Point-in-time
Other assets, net	`OtherAssetsNoncurrent`	$17.25M	USD	Point-in-time
Total Assets	`Assets`	$2.35B	USD	Point-in-time
Total Assets	`Assets`	$2.27B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.34M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$22.32M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$28.28M	USD	Point-in-time
Accrued compensation	`DeferredCompensationLiabilityCurrent`	$37.18M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$27.64M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$22.64M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$8.55M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$8.36M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$66.81M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$95.50M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$806.29M	USD	Point-in-time
Convertible senior notes, net	`ConvertibleDebtNoncurrent`	$1.13B	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$41.56M	USD	Point-in-time
Long-term operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$210.24M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.52M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.65M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.44B	USD	Point-in-time
Total Liabilities	`Liabilities`	$916.19M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$59.40M	USD	Point-in-time
Redeemable noncontrolling interest	`RedeemableNoncontrollingInterestEquityCarryingAmount`	$57.10M	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 101,085,653 and 100,213,985 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 101,085,653 and 100,213,985 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	`CommonStockValueOutstanding`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.56B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$1.90B	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$904.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$2.70M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-606.59M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-711.81M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$785.11M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$798.39M	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$1.30B	USD	Point-in-time
Total Stockholders Equity	`StockholdersEquity`	$847.05M	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.27B	USD	Point-in-time
Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$2.35B	USD	Point-in-time

Income Statement 40 line items

Line Item	Tag	Value	Unit	Period
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$60.25M	USD	1 Quarter
Precision oncology testing	`RevenuefromPrecisionOncologyTesting`	$63.73M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$14.94M	USD	1 Quarter
Development services and other	`RevenuefromDevelopmentServices`	$7.26M	USD	1 Quarter
Total revenue	`Revenues`	$67.51M	USD	1 Quarter
Total revenue	`Revenues`	$78.67M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$18.19M	USD	1 Quarter
Cost of precision oncology testing	`CostsofPrecisionOncologyTesting`	$23.59M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$5.16M	USD	1 Quarter
Cost of development services and other	`CostofDevelopmentServices`	$2.31M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$37.02M	USD	1 Quarter
Research and development expense	`ResearchAndDevelopmentExpense`	$55.51M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$25.11M	USD	1 Quarter
Sales and marketing expense	`SellingAndMarketingExpense`	$34.34M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$19.79M	USD	1 Quarter
General and administrative expense	`GeneralAndAdministrativeExpense`	$67.94M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$186.53M	USD	1 Quarter
Total costs and operating expenses	`CostsAndExpenses`	$102.42M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-107.86M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-34.91M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$1.55M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.32M	USD	1 Quarter
Interest expense	`InterestExpense`	$646.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$12.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-290.00K	USD	1 Quarter
Other expense, net	`OtherNonoperatingIncomeExpense`	$-209.00K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-31.82M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-107.25M	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$14.00K	USD	1 Quarter
Provision for (benefit from) income taxes	`IncomeTaxExpenseBenefit`	$110.00K	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Net loss	`ProfitLoss`	$-31.83M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$-4.10M	USD	1 Quarter
Adjustment of redeemable noncontrolling interest	`NetIncomeLossAttributableToRedeemableNoncontrollingInterest`	$2.30M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-109.66M	USD	1 Quarter
Net loss attributable to Guardant Health, Inc. common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-27.73M	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-0.29	USD	1 Quarter
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in usd per share)	`EarningsPerShareBasicAndDiluted`	$-1.09	USD	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	100.95M	shares	1 Quarter
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	94.38M	shares	1 Quarter

Cash Flow Statement 80 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Net loss	`ProfitLoss`	$-31.83M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$3.30M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$5.01M	USD	1 Quarter
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$3.93M	USD	1 Quarter
Non-cash operating lease costs	`NonCashOperatingLeaseCosts`	$1.50M	USD	1 Quarter
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	-	USD	1 Quarter
Charge of in-process research and development costs with no alternative future use	`ChargeOfInProcessResearchAndDevelopment`	$8.50M	USD	1 Quarter
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-190.00K	USD	1 Quarter
Re-valuation of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Non-cash stock-based compensation	`ShareBasedCompensation`	$6.34M	USD	1 Quarter
Non-cash stock-based compensation	`ShareBasedCompensation`	$55.07M	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$641.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	-	USD	1 Quarter
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-3.26M	USD	1 Quarter
Amortization of premium (discount) on marketable securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-580.00K	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	-	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-56.00K	USD	1 Quarter
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$-5.26M	USD	1 Quarter
Accounts receivable, net	`IncreaseDecreaseInAccountsReceivable`	$179.00K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$6.16M	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$9.97M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$2.60M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-521.00K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-1.20M	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-161.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$9.49M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$11.99M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$4.38M	USD	1 Quarter
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$8.90M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$4.40M	USD	1 Quarter
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-624.00K	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-1.86M	USD	1 Quarter
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-2.76M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-190.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-341.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.28M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-16.29M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$55.76M	USD	1 Quarter
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$70.65M	USD	1 Quarter
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$104.05M	USD	1 Quarter
Maturity of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$204.11M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$9.60M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$9.59M	USD	1 Quarter
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	-	USD	1 Quarter
Purchase of intangible assets and capitalized license obligations	`PaymentsToAcquireIntangibleAssets`	$17.89M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$123.87M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$20.80M	USD	1 Quarter
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$38.00K	USD	1 Quarter
Payments made on finance lease obligations	`FinanceLeasePrincipalPayments`	$55.00K	USD	1 Quarter
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$4.46M	USD	1 Quarter
Proceeds from issuance of common stock upon exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.50M	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	-	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$73.58M	USD	1 Quarter
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	$784.00K	USD	1 Quarter
Payment of offering costs related to borrowings on convertible senior notes	`PaymentsOfDebtIssuanceCosts`	-	USD	1 Quarter
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.47M	USD	1 Quarter
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-69.95M	USD	1 Quarter
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.00K	USD	1 Quarter
Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-1.09M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$36.54M	USD	1 Quarter
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$9.01M	USD	1 Quarter
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash and cash equivalentsBeginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$152.24M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Cash, cash equivalents and restricted cashEnd of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$152.24M	USD	Point-in-time
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$1.96M	USD	1 Quarter
Operating lease liabilities arising from obtaining right-of-use assets	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$170.85M	USD	1 Quarter
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$5.88M	USD	1 Quarter
Purchases of property and equipment included in accounts payable and accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$1.36M	USD	1 Quarter
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	$238.00K	USD	1 Quarter
Property and equipment acquired under finance leases	`PropertyPlantAndEquipmentAcquiredUnderFinanceLeases`	-	USD	1 Quarter
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$869.52M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$832.98M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$143.23M	USD	Point-in-time
Total cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$152.24M	USD	Point-in-time

Stockholders Equity 22 line items

Line Item	Tag	Value	Unit	Period
Reclassifications of Temporary to Permanent Equity	`ReclassificationsOfTemporaryToPermanentEquity`	$-2.30M	USD	1 Quarter
Reclassifications of Temporary to Permanent Equity	`ReclassificationsOfTemporaryToPermanentEquity`	$4.10M	USD	1 Quarter
Beginning balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Beginning balance	`StockholdersEquity`	$847.05M	USD	Point-in-time
Issuance of common stock upon exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	282,879.00	shares	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.50M	USD	1 Quarter
Issuance of common stock upon exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.46M	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Vesting of common stock exercised early	`StockIssuedDuringPeriodValueStockOptionsExercisedEarly`	$13.00K	USD	1 Quarter
Taxes paid related to net share settlement of restricted stock units	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$73.58M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$6.34M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$55.07M	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$6.59M	USD	1 Quarter
Other comprehensive gain (loss), net of tax impact	`OtherComprehensiveIncomeLossNetOfTax`	$-1.79M	USD	1 Quarter
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Net loss	`ProfitLoss`	$-31.83M	USD	1 Quarter
Ending balance	`StockholdersEquity`	$785.11M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$798.39M	USD	Point-in-time
Ending balance	`StockholdersEquity`	$1.30B	USD	Point-in-time
Ending balance	`StockholdersEquity`	$847.05M	USD	Point-in-time

Comprehensive Income 14 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-107.36M	USD	1 Quarter
Net loss	`ProfitLoss`	$-31.83M	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-706.00K	USD	1 Quarter
Unrealized gain (loss) on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$6.57M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$23.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax`	$-1.09M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$6.59M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-1.79M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-25.23M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-109.15M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$-4.10M	USD	1 Quarter
Comprehensive income (loss) attributable to redeemable noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$2.30M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-111.45M	USD	1 Quarter
Comprehensive loss attributable to Guardant Health, Inc.	`ComprehensiveIncomeNetOfTax`	$-21.14M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.